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Abstract 
Metastasis of gastrointestinal stromal tumor (GIST) into the central nervous 
system is extremely rare. We report a patient with synchronous GIST and brain 
metastasis. At disease onset, there was left hemiplegia and ptosis of the right 
eyelids. Resection cytology of the brain tumor was reported as metastasis of GIST. 
After positron emission tomography examination, another tumor in the small bowel 
was discovered, which suggested a small bowel GIST associated with intracranial 
metastasis. Immunohistochemical analysis of the intestinal tumor specimen obtained 
by double balloon endoscopy showed a pattern similar to the brain tumor, with the 
tumors subsequently identified as intracranial metastases of jejunal GIST. After surgical 
resection of one brain tumor, the patient underwent whole brain radiation therapy 
followed by treatment with imatinib mesylate (Gleevec; Novartis Pharma, Basel, 
Switzerland). Mutational analysis of the original intestinal tumor revealed there were 
no gene alterations in KIT or PDGFRα. Since the results indicated the treatment had no 
apparent effect on either of the tumors, and because ileus developed due to an intestinal 
primary tumor, the patient underwent surgical resection of the intestinal lesion. Case Rep Gastroenterol 2011;5:583–589 
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However, the patient’s condition gradually worsen and she subsequently died 4 months 
after the initial treatment. 
Introduction 
Gastrointestinal stromal tumors (GISTs) are the most common type of mesenchymal 
tumors in the gastrointestinal tract [1]. Their biological behavior correlates with 
clinicopathological parameters such as mitotic rate, tumor size and tumor location, as 
well as with the molecular alterations of KIT and PDGFR [2]. Imatinib is a potent, specific 
inhibitor of both the KIT and PDGFR receptor tyrosine kinase. The drug has been 
approved for the treatment of advanced unresectable or metastatic GIST. Since being 
approved for use in treatment, imatinib has dramatically improved the outcomes of 
advanced GIST patients [3]. Most metastasis arises in the liver and peritoneum, which is 
the result of hematogenous spread and peritoneal seeding, respectively. Disease outside 
the abdomen is uncommon and primarily seen in advanced cases only [2]. In addition, 
metastasis of GIST to the central nervous system is also extremely rare [4]. We report a 
rare case of intracranial metastasis from jejunal GIST. A PubMed database search only 
found 7 reported cases of brain metastases from primary GIST. Here, we report a 
summary of the relevant literature that is currently available. 
Case Report 
A 77-year-old woman presented in December 2009 with left hemiplegia and ptosis of her right 
eyelids. Magnetic resonance imaging (MRI) of the brain revealed a 24 mm tumor in her right cerebral 
peduncle and a 20 mm tumor in her left occipital lobe, which was associated with brain edema (fig. 1). 
On the basis of the radiologic features of the computed tomography (CT) and MRI procedures, she was 
initially diagnosed as having a malignant lymphoma in her brain. Subsequently, the tumor in her left 
occipital lobe was completely resected. Histopathological examination of the hematoxylin and eosin 
specimen revealed a spindle cell tumor. Since immunohistochemistry was positive for c-kit and negative 
for CD34, desmin and S-100 (fig. 2), she was diagnosed with metastasis of GIST. After counting the 
proliferating cells that were immunostained by Ki-67 (MIB-1) antibody, her MIB-1 index was 
determined to be approximately 20% (fig. 2). A positron emission tomography computed tomography 
(PET-CT) examination revealed the presence of another tumor in the small bowel (fig. 3a), which 
suggested small bowel GIST associated with intracranial metastasis. Since capsule endoscopy revealed a 
tumor in the proximal jejunum, oral endoscopy using the double balloon technique was carried out. 
The proximal jejunum demonstrated a 3 cm oval-shaped mass which was consistent with the findings 
obtained by capsule endoscopy (fig. 3b). Subsequent pathological examination found a malignant 
spindle cell tumor with morphology that was similar to that of the brain tumor. Immunohistochemical 
staining demonstrated that the tumor cells were positive for c-kit while negative for CD34, desmin and 
S-100. This was consistent with the findings for the brain tumor. Therefore, the patient was diagnosed 
as having a primary jejunal GIST associated with brain metastasis. Mutational analysis of the intestinal 
tumor was carried out and no mutations were found in the KIT exons 11, 13, 17, 19 or for PDGFRα. 
Postoperatively, the patient underwent whole brain radiation therapy in conjunction with 
administration of imatinib mesylate 400 mg/day in February 2010. Unfortunately, she suffered from 
leucopenia 1 month after initiation of imatinib methylate administration and the drug had to be 
discontinued. The patient remained well until the end of March 2010, when she began to complain of 
abdominal pain. CT examination revealed the development of ileus due to the jejunal primary tumor, 
leading to surgical resection of the intestinal lesion. Observation during the surgery revealed that the 
tumor in the proximal jejunum had not changed in size compared to the size observed during the 
previous double balloon endoscopy. Although there was minor enlargement of her right cerebral 
peduncle tumor, brain MRI at that time showed no apparent recurrence in the left occipital lobe where Case Rep Gastroenterol 2011;5:583–589 
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tumor resection had been performed. The patient’s condition gradually worsened and she died 
4 months after the initial treatment. 
Discussion 
GISTs are the most common mesenchymal neoplasms in the gastrointestinal tract. 
GISTs arise from the precursor cells of the interstitial cells of Cajal and express KIT 
tyrosine kinase. Most GISTs express Kit (94%), CD34 (82%), with 78% of GISTs positive 
for both KIT and CD34 [1]. Activating mutations of KIT or PDGFRα are found in the 
vast majority of GISTs, and the mutational status of these oncoproteins can be predictive 
of the clinical response to imatinib therapy [1, 3, 5]. Although KIT exon 11 is the most 
common mutation found in GISTs (66.9%), other exons harboring mutations, such as 
exon 9 (18.1%) and exons 13 and 17 (1.6%), have also been described [3, 6]. The response 
and sensitivity to imatinib in GISTs that lack KIT mutations has been reported to be due 
to the PDGFRα mutations [5]. It has also been shown that the reason why imatinib 
mesylate is not effective in treating metastatic GIST in the brain is because of the presence 
of the blood brain barrier. Lower concentrations of imatinib mesylate in the central 
nervous system have been detected in both mice [7] and humans [8]. In addition, a small 
population of GISTs have been discovered that lack both the KIT and PDGFRα mutations 
[5], and when these populations are treated with imatinib, a very poor response is 
observed [3]. Consistent with these reports, our patient also exhibited no mutations in 
either the KIT exon 7, 9, 11, 13 or PDGFRα, and she was resistant to imatinib mesylate 
treatment.  
While GIST frequently metastasizes to both the liver and peritoneum, metastasis 
outside the abdomen is very uncommon [2]. There have also been very few reports in the 
literature regarding concurrent GIST and brain metastasis. A current review of the 
literature found only 7 case reports including the current case [4, 9–13]. To verify our 
present observations, we compared the findings presented for all of the reported cases in 
the literature (table 1). In all cases, patients underwent administration of imatinib 
mesylate, with only 1 out of the 7 cases exhibiting a response to the chemotherapy [12]. 
However, since most of these cases primarily involved brain metastasis, the molecular 
features were not described [11]. Mutational analysis was described in case report 5, in 
which a mutation in exon 9 of KIT was detected in the original jejunal tumor, the liver 
and the cerebral metastases. It is well known that GISTs with different mutations will 
show different clinical characteristics. However, the prognostic significance of KIT 
mutations remains controversial, as Cho et al. [14] reported that KIT-mutation-positive 
GISTs exhibit more frequent liver metastases and a higher mortality than KIT-mutation-
negative GISTs. Braconi et al. [6] found in 104 patients that 74% of the exon 11 KIT 
mutations were associated with metastasis, as compared to only 5% of the wild-type 
GISTs. PDGFRα mutations rarely result in metastatic disease [6], and thus, to the best of 
our knowledge, this is the first report that found GIST occurring without any KIT or 
PDGFRα mutations associated with the intracranial metastasis. Recently, it has been 
shown that the transcription factor ETV1 is necessary for the survival and growth of GIST 
cells in vitro and in vivo [15]. Since all GIST samples and GIST cell lines express ETV1, 
this transcription factor might very well be a new biomarker and therapeutic target for 
GIST. Thus, in the absence of mutations in either KIT or PDGFRα, as was seen in our Case Rep Gastroenterol 2011;5:583–589 
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case, other factors such as ETV1 might be involved in the promotion and metastasis of 
GIST. 
Being able to elucidate the mechanism of tumorigenesis and to identify the responsible 
gene in GISTs that exhibit no detectable mutations of KIT or PDGFRα may lead to new 
insights into the nature of GIST and potentially a novel diagnosis and therapy. In 
summary, we histologically confirmed the brain metastasis of small bowel GIST in the 
current case, which is a rare and particularly unusual manifestation of this tumor. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Case Rep Gastroenterol 2011;5:583–589 
DOI: 10.1159/000333403 
Published online: 
October 4, 2011 
© 2011 S. Karger AG, Basel
ISSN 1662–0631 
www.karger.com/crg   
 
 
 
587
Table 1. Metastatic GISTs in the central nervous system (CNS) 
Primary   CNS    No. Age/ 
gender 
site  size (cm)   site  size (cm)   
Treatment for CNS tumor  Mutational  
status 
Response of 
CNS tumor 
Reference 
1  75/M  mesentery  ND    hemisphere  (infiltrative)  imatinib 800 mg/day  NA  CR  Brooks et al.
[12], 2002  
2  47/M jejunum  7.5   left  parasagittal   
lesion 
ND    total resection, imatinib  
400–800 mg/day 
exon 9  PD  Hughes et 
al. [9], 2004 
3 68/F perisacral   
area 
ND    right parietal lobe  3    total resection, imatinib  NA  SD  Kaku et al.  
[10], 2006 
4  42/M  mesentery  8×6    right parietal lobe  3.5    total resection, radiotherapy  
60 Gy, imatinib 600 mg/day 
NA  PD  Puri et al. 
[4], 2006 
5  49/F  mesentery  ND    left eye, brain  0.24    imatinib 400 mg/day  NA  PD  Gentile et al.
[13], 2008 
6  54/F  esophagus  11    left frontal lobe  5    complete resection, imatinib 
400 mg/day 
exon 11  SD  Hamada  
et al. [11], 
2010 
7  77/M jejunum  3   right  cerebral   
peduncle 
left occipital lobe 
2.4 
 
2 
  total resection of left occipital 
lobe tumor, radiation therapy 
39 Gy, imatinib 400 mg/day 
no mutation  
in KIT,  
PDGFRα 
PD our  case, 
2011 
ND = Not determined; NA = no analysis; CR = complete response; PD = progressive disease; SD = stable disease. 
 
 
 
 
 
Fig. 1. Axial MRI of the brain shows solid tumors in the right cerebral peduncle and in the left occipital 
lobe with surrounding cerebral edema. 
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Fig. 2. Tumor cells stained with hematoxylin and eosin at 100× magnification (a). Spindle-shaped cells 
with oval nuclei are arranged in storiform architecture. Under higher magnification, 10/high power field 
nuclear differentiations were observed. Brown-staining spindle cells are positive for KIT (b) and 
negative for CD34 (c), desmin (d) and S-100 (e). Approximately 20% were MIB-1-labeled proliferating 
cells (f). 
 
 
 
Fig. 3. a PET-CT showed there was an abnormal uptake, with a standardized uptake value maximum 
of 6.8 in the proximal jejunum. b Double balloon endoscopy identified an oval-shaped mass 
approximately 3 cm in diameter at the proximal jejunum. 
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